Page 3 - Themis Bioscience News Today

When Merck announced in May that it was a late entrant in the race to develop a COVID-19 vaccine, the American pharmaceutical giant was a popular pick to win.

Drugmaker Merck & Co said on Monday it would stop development of its two COVID-19 vaccines and focus pandemic research on treatments, with initial data on an experimental oral antiviral expected by the end of March.

/PRNewswire/ -- PitchBook, the premier data provider for the private and public equity markets, today released its 2020 Annual European Venture Report, which...

Drugmaker Merck & Co on Monday said it will end development of its two COVID-19 vaccines, and will focus pandemic research on treatments, with initial efficacy data on an experimental oral antiviral expected by the end of March. Merck said in a statement it will record a pretax discontinuation charge in the fourth quarter for vaccine candidate V591, which it acquired with the purchase of Austrian vaccine maker Themis Bioscience, and V590, developed with nonprofit research organization IAVI. In ...

3 Min Read Jan 25 (Reuters) - Drugmaker Merck & Co on Monday said it will end development of its two COVID-19 vaccines, and will focus pandemic research on treatments, with initial efficacy data on an experimental oral antiviral expected by the end of March. Merck said in a statement it will record a pretax discontinuation charge in the fourth quarter for vaccine candidate V591, which it acquired with the purchase of Austrian vaccine maker Themis Bioscience, and V590, developed with nonprofit r...

Merck is shutting down the programs linked to its two COVID-19 vaccine candidates following early trial data indicating that they failed to generate immune responses comparable to a natural infection or existing vaccines. One of its candidates against COVID-19 was called V590; it built on Merck’s Ebola inoculation platform, while the other one, V591, was based on a measles vaccine used in Europe. Merck, known as MSD outside of the US and Canada, will record a preta...

Share: New York, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Cancer Vaccines Global Market Report 2020-30: COVID-19 Growth and Change" - https://www.reportlinker.com/p05995337/?utm_source=GNW 21 billion in 2019 to $4.89 billion in 2020 at a compound annual growth rate (CAGR) of -6.16%. The decline is mainly due to the COVID-19 outbreak that has led to restrictive containment measures involving social distancing, remote working, and the closure of in...